Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation-Reference-Cited by-同舟云学术

Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation

Published:2019-03-30 Issue:6 Volume:8 Page:e1593801
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Fan Lei¹,Zhou Peng²,Hong Qi¹,Chen Ao-Xiang¹,Liu Guang-Yu¹,Yu Ke-Da¹,Shao Zhi-Ming¹

Affiliation:

1. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, P.R. China

2. Department of Ophthalmology, Parkway Health, Shanghai, P.R.China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1593801

Reference54 articles.

1. Breast cancer in China

2. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China

3. Toll-Like Receptors

4. TLR3: Interferon induction by double-stranded RNA including poly(I:C)☆

5. mRNA Is an Endogenous Ligand for Toll-like Receptor 3

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of genetic variations in Toll-Like receptor 3 with Acute Lymphoblastic leukemia;Journal of King Saud University - Science;2024-09

2. Toll-like receptors in breast cancer immunity and immunotherapy;Frontiers in Immunology;2024-06-06

3. Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial;Clinical and Translational Medicine;2024-05

4. Toll‐like receptors in health and disease;MedComm;2024-04-29

5. Immune Checkpoint Inhibitors in Triple-negative Breast Cancer;Nature Cell and Science;2023-12-30